Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma
Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This is a single center, non-randomized phase IIa study to determine the tolerance and safety
of Abraxane (ABX) in combination with cisplatin (DDP) in patients with advanced
nasopharyngeal carcinoma (NPC). Patients in whom the standard therapy had failed or had been
infeasible will be eligible.The safety and efficacy will be evaluated according to NCI-CTCAE
V4.0 and RECIST 1.1 respectively.